Ilhan-Mutlu, Aysegül http://orcid.org/0000-0001-8291-0873
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 15 July 2021
Accepted: 30 August 2021
First Online: 8 October 2021
Conflict of interest
: A. Ilhan-Mutlu participated in advisory boards from MSD, BMS and Servier, received lecture honoraria from Eli Lilly, MSD, BMS and Servier, is the local PI for clinical trials sponsored by BMS and Roche and received travel support from BMS, Roche, Eli Lilly and Daiichi Sankyo.
: ASCO 2021 included several phase III clinical trials with positive results which will change the treatment algorithm of gastroesophageal cancer patients, both for localized and advanced settings.